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In Brief
Intravital imaging facilitates the real-time
tracking and targeting of moving hypoxic
regions within pancreatic ductal
adenocarcinoma. Using this approach,
Conway et al. alleviate hypoxia-induced
resistance to a dual mTORC1/2 inhibitor
AZD2014, improving PI3K pathway
inhibition and demonstrating a powerful
dual imaging modality applicable to
targeting other pathways and cancers.
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Application of advanced intravital imaging facilitates
dynamic monitoring of pathway activity upon thera-
peutic inhibition. Here, we assess resistance to
therapeutic inhibition of the PI3K pathway within
the hypoxic microenvironment of pancreatic ductal
adenocarcinoma (PDAC) and identify a phenomenon
whereby pronounced hypoxia-induced resistance is
observed for three clinically relevant inhibitors. To
address this clinical problem, we have mapped tu-
mor hypoxia by both immunofluorescence and phos-
phorescence lifetime imaging of oxygen-sensitive
nanoparticles and demonstrate that these hypoxic
regions move transiently around the tumor. To over-
lay this microenvironmental information with drug
response, we applied a FRET biosensor for Akt activ-
ity, which is a key effector of the PI3K pathway.
Performing dual intravital imaging of drug response
in different tumor compartments, we demonstrate
an improved drug response to a combination therapy
using the dual mTORC1/2 inhibitor AZD2014 with the
hypoxia-activated pro-drug TH-302.
INTRODUCTION
A recurring feature in malignant cancers is the aggressive
alterations that cells undergo in order to survive in a low-oxygen
(hypoxic) environment. This hypoxic environment is commonly a
result of insufficient tumor vascularity and is strongly associated
with increased radioresistance, chemoresistance, and metas-
tasis (Rofstad et al., 2007; Sullivan et al., 2008; Wilson and3312 Cell Reports 23, 3312–3326, June 12, 2018 Crown Copyright ª
This is an open access article under the CC BY license (http://creativeHay, 2011). Among those cancers with a propensity for high
levels of tumor hypoxia, pancreatic ductal adenocarcinoma
(PDAC) has a well-established hypoxic signature, which is pre-
dictive of poorer patient prognosis (Chang et al., 2011; Miller
et al., 2015). PDAC has a poor 5-year survival of less than 8%
and is predicted to be the second leading cause of cancer-
related deaths by 2030 (Rahib et al., 2014; Siegel et al., 2017).
One approach to improve patient outcome has been to target
hypoxic tumor regions in order to improve both drug penetrance
and response (Chen et al., 2016; Sun et al., 2015). Hypoxia-
activated pro-drugs (HAPs) provide an efficient method to
specifically deliver cytotoxic agents to hypoxic tumor regions,
diminishing the off-target effects from conventional small-
molecule therapeutics (O’Connor et al., 2016; Wilson and Hay,
2011). These HAPs may also affect normoxic tumor regions by
virtue of a local bystander effect and in this way provide an
even more versatile approach for targeted delivery (Abbattista
et al., 2015; Sun et al., 2015). Cytotoxic mustard-based HAPs,
such as TH-302 (Meng et al., 2012; Sun et al., 2015) and
PR-104 (Abbattista et al., 2015), are currently the most widely
applied, building on the ushering work of tirapazamine and
related derivatives (Kovacs et al., 1999; Wilson and Hay, 2011).
Recently, we have seen an emergence of bioreductive groups
attached to targeted therapeutics, concomitant with improve-
ments in their synthesis and sensitivity (O’Connor et al., 2016;
Wilson and Hay, 2011). However, HAPs are generally insufficient
for use as monotherapies, and current clinical trials focus on
their application in combination with chemotherapeutics, radio-
therapy, or targeted therapies (Borad et al., 2015; Van Cutsem
et al., 2016; Wilson and Hay, 2011).
In recent work, we demonstrated that targeting of the
phosphatidylinositol 3-kinase (PI3K) pathway with the dual
mTORC1/2 inhibitor AZD2014 presents a therapeutic opportu-
nity for PDAC, equivalent to the standard-of-care gemcitabine2018
commons.org/licenses/by/4.0/).
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Figure 1. The Presence of Hypoxia and the Associated Molecular, Phenotypic, and Resistance Effects in the KPflC and KPC Mouse
Models of PDAC
(A) Immunofluorescence staining of the GEMKPflC and KPC PDACmousemodels for Akt(Ser473) (red), DAPI (cyan), and pimonidazole (green). Scale bars, 50 mm.
(legend continued on next page)
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(Driscoll et al., 2016). This built upon our previous work,
whereby the mTORC1 inhibitor rapamycin showed improved
efficacy in tumors with high PI3K pathway activity (Kennedy
et al., 2011; Morran et al., 2014). There is a well-established
role for the PI3K pathway in hypoxia, which is linked with che-
moresistance, metabolic reprogramming, and angiogenesis
(Chae et al., 2016; Guo et al., 2016). Here, we identify a phe-
nomenon whereby two aggressive PDAC models were resistant
to three clinically relevant PI3K pathway inhibitors, when
grown in a hypoxic environment. We investigate this resistance
within a three-dimensional (3D) organotypic co-culture system
(Conway et al., 2014; Morton et al., 2010; Vennin et al., 2017)
and confirm that resistance to PI3K pathway inhibition only
occurred in hypoxic cells invading into the matrix. Furthermore,
we reveal that hypoxia moves transiently around the tumor
in vivo and this pocket of resistance presents a potential
moving target in PDAC.
To combat this hypoxia-induced resistance, we developed a
combination therapy that combines the dual PI3K pathway
inhibitor AZD2014 with the HAP TH-302. This combination
reduces the hypoxia-induced resistance to AZD2014 in vitro
and significantly inhibits tumor growth in vivo. To elucidate
the improved outcomes from this combination therapy, we
performed live intravital microscopy (IVM) of drug-target
activity using an intramolecular Fo¨rster resonance energy trans-
fer (FRET) biosensor for Akt activity (Komatsu et al., 2011).
Monitoring drug response in individual cells by fluorescence
lifetime imaging microscopy (FLIM)-FRET, in parallel with phos-
phorescence lifetime imaging microscopy (PLIM) of oxygen-
sensitive nanoparticles (Conway et al., 2017; Kondrashina
et al., 2012), enabled the stratification of single-cell responses
within different tumor compartments. This demonstrated that
regions with poorer drug response also had lower oxygen con-
tent. Furthermore, when tumor-bearing mice were treated in
combination with the HAP TH-302 and AZD2014, Akt activity
was further reduced, compared to AZD2014 monotherapy.
Critically, these findings highlight both the value of combining
targeted therapeutics with HAPs and the preclinical power of
IVM in the drug discovery pipeline (Conway et al., 2014; Miller
and Weissleder, 2017).
RESULTS
Hypoxia Induces Resistance to PI3K Pathway Inhibition
in PDAC
Hypoxia is a common feature of PDAC and are often associated
with malignant disease (Chang et al., 2011; Miller et al., 2015).
Hypoxia is regularly the result of a disorganized vascular network(B) Quantification of Akt(Ser473) grey value/cell in pimonidazole negative (normo
p values are from a one-sample t test.
(C) Propidium iodide staining of cell cycle phase distribution in the KPflC and KPC
way ANOVA with a Tukey correction for multiple comparisons.
(D) Representative western blots of the KPflC and KPC primary PDAC cell lines,
(E) A simplified schematic of the PI3K pathway, indicating the targets of the PI3K
(F and G) IC50 curves demonstrating the response of KP
flC (F) and KPC (G) prim
and AZD2014, in both normoxic (black lines) and hypoxic (0.1% oxygen, red lines)
best-fit parameters of each curve.
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S1.
3314 Cell Reports 23, 3312–3326, June 12, 2018within the tumor and, in the extreme case of anoxia (no oxygen),
may lead to necrosis (Wilson and Hay, 2011). To investigate
the role of hypoxia in PDAC, we used the well-established non-
invasive LSL-KrasG12D/+, LSL-Trp53fl/+, Pdx1-Cre (KPflC) and
invasive LSL-KrasG12D/+, LSL-Trp53R172H/+, Pdx1-Cre (KPC)
genetically engineered mouse (GEM) models (Hingorani et al.,
2003, 2005; Morton et al., 2010). These PDAC models possess
driver mutations in Kras and loss or gain-of-function mutation
of the tumor suppressor gene Trp53, which occur in 95%
and 75% of human PDAC cases, respectively (Hingorani
et al., 2005;Morton et al., 2010;Waddell et al., 2015). This altered
p53 function has been associated with improved survival of
cancer cells in hypoxic conditions (Leszczynska et al., 2015).
However, we found no significant difference in the fraction of
Ki67-positive cells between hypoxic and normoxic regions of
tumors in either model, as stratified by pimonidazole staining
(Figure S1A; quantified in Figure S1B) (Varia et al., 1998). Impor-
tantly, we observed a significant upregulation in Akt activity in
hypoxic regions of the GEM PDACmodels (Figure 1A; quantified
in Figure 1B), in line with previous reports (Chae et al., 2016; Guo
et al., 2016).
Primary cell lines with loss or gain of function of p53 (Fig-
ure S1C), previously isolated from both PDAC mouse models,
were assessed for their response to hypoxia at 5%, 1%, and
0.1% oxygen (Morton et al., 2010). A small decrease in S phase
at decreasing oxygen levels was observed for both cell lines
when performing cell cycle analysis by fluorescence-activated
cell sorting (FACS) (Figure 1C). To assess whether the slight
reduction in S phase conferred a decrease in cell number, we
quantified cells in 0.1% oxygen and found no significant
decrease in cell number, compared to normoxia (Figure S1D).
Furthermore, decreasing oxygen levels were not found to have
a significant effect on apoptosis in either of the PDAC cell lines,
assessed by Annexin V staining (Figure S1E).
As anticipated, we observed a significant increase in HIF1a
stabilization at 5%, 1%, and 0.1% oxygen (Figure 1D; quantified
in Figure S1F), and a graded increase in pimonidazole adduct
formation (Figure S1G; quantified in Figure S1H). Having estab-
lished a hypoxic response, we assessed the activity of the
PI3K pathway and identified a significant upregulation of Akt ac-
tivity in hypoxia in both cell lines (Figure 1D; quantified in Figures
S1I and S1J). Conversely, looking downstream of mTORC1,
phosphorylation of p70-S6K was significantly reduced, consis-
tent with previous reports (Figure 1D; quantified in Figure S1K)
(Faes et al., 2016). These data confirm a role for the PI3K
pathway in the hypoxic response within our models and promp-
ted assessment of therapeutic inhibition of the PI3K pathway
within this hypoxic environment.xic) and positive (hypoxic) regions (n = 5 tumors/mouse model). Mean ± SEM.
primary PDAC cell lines. Mean ± SEM. p values were calculated using a two-
incubated for 48 hr in normoxia or hypoxia (5%, 1%, or 0.1% oxygen; n = 5).
pathway inhibitors used in this study.
ary PDAC cell lines to the PI3K pathway inhibitors rapamycin, NVP-BEZ235,
conditions (n = 3). An extra sum-of-squares F test was performed between the
We employed three clinically relevant inhibitors of the PI3K
pathway, namely, rapamycin, NVP-BEZ235, and AZD2014 (Fig-
ure 1E). These inhibitors allowed us to targetmultiple levels of the
PI3K pathway to provide a broader assessment of therapeutic
response (Figures 1E–1G). Evaluating the half-maximal inhibitory
concentration (IC50) for each inhibitor in both hypoxia and nor-
moxia, we found that primary PDAC cell lines from each model
showed hypoxia-induced resistance to all three PI3K pathway-
targeted therapeutics (Figures 1F and 1G).
3D Assessment of Hypoxia-Induced Resistance in
Invasive KPC PDAC Cells
The KPC PDAC model recapitulates the invasive and metastatic
phenotype that is frequently observed in the clinical management
of this disease (Hingorani et al., 2003, 2005; Morton et al., 2010).
We therefore used 3D organotypic invasion assays to assess the
effects of targeting the PI3K pathway in the invasive KPC cells
(Conway et al., 2014; Morton et al., 2010; Vennin et al., 2017). To
confirm the presence of hypoxia within our 3D organotypic
matrices, KPC cells were seeded and allowed to grow on fibro-
blast-contractedmatrices for 4daysbeforemounting thematrices
on an air-liquid interface, which promotes invasion toward the
chemo-attractive media (Figure 2A) (Conway et al., 2014; Morton
et al., 2010; Vennin et al., 2017). Interestingly, staining for hypoxia
within the organotypic matrices demonstrated a clear gradient of
decreasing oxygen content from the surface of the matrix (see
‘‘Normoxia,’’ Figure 2A) to the invading cells within the matrix
(see ‘‘Hypoxia,’’ Figure 2A). To confirm that this gradient was not
a result ofpoordiffusionofpimonidazole into thematrix,we treated
organotypic matrices with the fluorescent probe laurdan, as well
as the autofluorescent drug doxorubicin (Figures S2A and S2B).
In both cases, fluorescence of each compoundwas visible in cells
on the surface and within the matrix (Figures S2A and S2B).
To further corroborate the presence of a hypoxic gradient, we
stained our organotypics for expression of GLUT1 and lactate
dehydrogenase (Figures S2C and S2D). These proteins are typi-
cally upregulated under hypoxic conditions and were found to be
upregulated in hypoxia (5%, 1%, and 0.1% oxygen) in the KPC
cells (Figure S2E; quantified in Figure S2F) (Shukla et al., 2017).
Next, cells invading into organotypicmatriceswere treatedwith
each PI3K pathway inhibitor (Figure 2B). Supporting our IC50
curves, the cells on the surface of thematrix (‘‘Normoxia’’) demon-
strated a significant reduction in Ki67 staining for all inhibitors,
while cells invading into the organotypic matrices (‘‘Hypoxia’’)
were resistant to the inhibitors (Figure 2B, inset: see blue arrows
and note reduction in Ki67-positive cells in normoxia for all inhib-
itors, which was less evident in hypoxia [see red arrows]; quanti-
fied in Figure 2C). Furthermore, treatment with rapamycin and
NVP-BEZ235 yielded a subtle yet significant decrease in invasion,
while AZD2014 induced a robust anti-invasive effect (Figure 2B;
quantified in Figure 2D). Taken together, we found a common
hypoxia-induced resistance to PI3K pathway targeting within
our 3D organotypic matrices.
Therapeutic Response of PDAC Cells Treated with
AZD2014 Is Improved by the HAP TH-302
After confirming the hypoxia-induced resistance to PI3K
pathway inhibition within the 3D organotypic assay, we choseto combat this resistance in a combination therapy. An attractive
option for targeting the resistant hypoxic compartment is
through the use of HAPs, which provide additional benefits
with minimal toxicity to normoxic tissues (Abbattista et al.,
2015; Meng et al., 2012; Wilson and Hay, 2011). We selected
the dual mTORC1/2 inhibitor AZD2014 to develop a combination
therapy with the HAP TH-302. TH-302 has already been shown
to improve mTOR-targeted therapies in renal cell carcinoma
(Sun et al., 2015), and within our models, AZD2014 alone has
demonstrated a clear survival benefit, equivalent to that of gem-
citabine (Driscoll et al., 2016). Here, we identified an additional
anti-invasive effect provided by AZD2014 (Figure 2D, see blue
bar), which may address the clinical need to reduce invasion
and metastasis in PDAC patients. We next assessed the effect
of TH-302 alone on KPC cells (Figure S2G). As expected,
TH-302 showed a greatly reduced IC50 in hypoxia, compared
to normoxia, consistent with an increased potency in hypoxia
(Figure S2G) (Meng et al., 2012). We then assessed the effect
of TH-302 on the hypoxia-induced resistance of AZD2014 (Fig-
ures 2E–2I). Having established the presence of a hypoxic
gradient within our organotypic matrices (Figure 2A), we as-
sessed the effect of combining TH-302 with AZD2014 in a 3D
environment (Figures 2E and 2F). In combination, the anti-
proliferative effects of both inhibitors were significantly improved
overall (Figure 2G, compare red and blue bars to green). Upon
further analysis, we found hypoxia-induced resistance to
AZD2014 for cells within the matrix (Hypoxia), which was signif-
icantly reduced in combination with TH-302 (Figure 2F, inset: see
red arrows). In contrast, TH-302 treatment led to a 50%decrease
in Ki67-positive cells within the matrix (Hypoxia), which did not
occur on the surface of the matrix (Figure 2F, inset, see red/
blue arrows; Figures 2H and 2I, compare black bars to red).
Furthermore, we assessed the effect of AZD2014 on the PI3K
pathway by staining matrices for the downstream stress
response gene NDRG1(Thr346). This staining highlighted a sig-
nificant downregulation of NDRG1 activity in the combination
therapy, compared to AZD2014 alone (Figure S2H). Consistent
with a role in stress response, NDRG1 was also shown to be up-
regulated in decreasing oxygen levels (Figure S2E; quantified in
Figure S2F), as well as in cells within the matrix (Figure S2H,
inset: compare frequently negatively stained cells on the surface
of thematrix ‘‘Normoxia,’’ to darkly stained cells within thematrix
‘‘Hypoxia’’). Moreover, to confirm the activity of TH-302 within
the matrix, gH2AX staining was performed and demonstrated a
significant upregulation in DNA damage response within the or-
ganotypicmatrices for TH-302 and the combination therapy (Fig-
ure S2I). These data are consistent with the activity of TH-302
increasing within the lower oxygen environment of the organo-
typic matrix, where it plays a significant role in alleviating the
overall hypoxia-induced resistance to AZD2014 (Figures 2F–2I).
In Vivo Assessment of Subcutaneous PDAC Tumors
Treated with AZD2014 in Combination with the HAP TH-
302
Guided by the spatial response of the combination therapy iden-
tified in our 3D organotypic matrices, we investigated whether
this effect was recapitulated in vivo. KPC tumor-bearing mice
were treated with a combination of AZD2014 (2.5 mg/kg) andCell Reports 23, 3312–3326, June 12, 2018 3315
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Figure 2. Organotypic Invasion Assay of KPC Cells Treated with PI3K Pathway Inhibitors and/or TH-302
(A) A schematic representation of the organotypic matrix assay and a representative area of invading KPC cells stained with pimonidazole (a marker of hypoxia).
(B) Representative images of invading KPC cells stainedwith the epithelial cell marker pan-cytokeratin or the proliferativemarker Ki67. Scale bars, 100 mm; insets,
25 mm.
(C) Normalized Ki67 staining from the same experiments scored for cells on top of the organotypic matrix (normoxia) and cells invading into the matrix (hypoxia).
Mean ± SEM.
(D) Normalized invasive index of KPC cells treated with NVP-BEZ235, AZD2014, or rapamycin (n = 3). Mean ± SEM.
(E and F) Representative images of invading KPC cells stained with the hypoxia marker pimonidazole (E) or the proliferative marker Ki67 (F). Scale bars, 50 mm;
insets, 10 mm. Mean ± SEM.
(G) Quantification of Ki67-stained KPC cells invading into organotypic matrices (n=4).
(H and I) Assessment of Ki67-stained KPC cells either on top of (H, normoxia) or invading into (I, hypoxia) organotypic matrices (n = 4). A one-sample t test was
performed on normalized data in all panels.
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S2.TH-302 (50 mg/kg). Here, we observed a significant decrease in
both tumor growth and Ki67 positivity within the combination-
treated tumors, compared to AZD2014 monotherapy (Figures
3A–3C). Previous work has demonstrated that the DNA cross-
linking effect of TH-302 is associated with an increase in
gH2AX-positive cells, consistent with activation of the DNAdam-3316 Cell Reports 23, 3312–3326, June 12, 2018age response (Meng et al., 2012; Sun et al., 2015). In agreement,
TH-302 treatment resulted in a significant increase in gH2AX-
positive cells in this study (Figure 3D). Interestingly, AZD2014
alone also caused a significant increase in gH2AX-positive cells,
in line with the known role of the PI3K pathway in sensitizing cells
to DNA damage (Figure 3D) (Sun et al., 2015). Similarly, both the
FE
C
D
H
G
A B
(legend on next page)
Cell Reports 23, 3312–3326, June 12, 2018 3317
mono- and combination therapies showed an increase in necro-
sis, compared to vehicle treatment (Figure 3E). We concluded
that both drugs were working as expected within the tumors,
but the benefit of TH-302 combination therapy over AZD2014
monotherapy was not provided by an increased sensitization
of cells to DNA damage.
We then assessed whether the reduced fraction of Ki67-
positive cells between AZD2014 alone or in combination with
TH-302 (Figure 3C) was due to a reduction in the hypoxic burden
of the tumor. Assessing the hypoxic fraction of the tumors by
pimonidazole staining, we observed a significant decrease be-
tween AZD2014 alone and the combination (Figure 3F, compare
blue bar to green). This modest change seemed unlikely to be
the only factor involved in the observed differences between the
treatments. Moreover, it is important to note that pimonidazole
is a marker of very low oxygen content and does not always coin-
cidewith the subtle changes in hypoxic response pathwayswithin
the cell (Figures S1G and S1H) (Varia et al., 1998; Wilson and Hay,
2011). To assess this more directly, we stained for HIF1a, which is
responsible for mounting much of the cellular hypoxic response.
This staining revealed a significant decrease in the fraction of cells
actively responding to a low oxygen environment, in both TH-302
alone and combination treatments (Figure 3G). Furthermore,
staining for carbonic anhydrase IX (CAIX), an important down-
stream component of the cellular pH-regulatory response in hyp-
oxia (Parks et al., 2017), coincided with a significant decrease in
CAIX expression in the mono- and combination therapies (Fig-
ure 3H). Additionally, to assess whether the derived benefit of
the combination was a result of changes in vasculature, we quan-
tified the coverage ofmicrovessels stained for CD31 and found no
significant difference between the treatments (Figure S3A).
While these changes may be acting additively to elicit the
growth inhibition and decreased Ki67 positivity in the combina-
tion therapy,wealso assessedwhether therewas acombined ef-
fect of each treatment on the cell cycle. Initially, we scored the
number of cells with fragmented nuclei in each condition and
found a significant increase, which may indicate a higher rate of
mitotic failure (Figure S3B). This led us to assess the effect of
our therapies on mitotic progression, through HistoneH3(Ser10)
staining (Figure 4A). By this approach, we found a significant up-
regulation of HistoneH3(Ser10)-positive cells in the TH-302 treat-
ments and a significant downregulation in the AZD2014 treat-
ments (Figure 4A). Upon further phenotypic assessment of the
specific stages, from late G2 through to anaphase, we found
that TH-302 causes cells to accumulate in late G2 at the initiation
of mitosis, observing increased focal staining of Histo-
neH3(Ser10) within nuclei (Figures 4B–4E) (Hendzel et al.,Figure 3. Assessment of KPC Subcutaneous Xenografts Treated with
(A and B) Tumor volume measurements (A) and average linear growth rate (B)
AZD2014/saline (n = 10), and AZD2014/TH-302 (n = 10).
(C and D) Immunohistochemistry (IHC) staining of drug response in tumors ass
damage response (gH2AX, n = 5 tumors/treatment) (D). Scale bars, 100 mm; inse
(E and F) Staining for the necrotic (using H&E) (E) and hypoxic (pimonidazole
AZD2014/saline (n = 10), and AZD2014/TH-302 (n = 10) treatments. Scale bars
(G) HIF1a (n = 5 tumors/treatment) IHC staining of tumors. Scale bars, 100 mm; i
(H) Carbonic anhydrase IX (CAIX) IHC staining of tumors from vehicle/saline (n =
(n = 10) treatments. Scale bars, 100 mm; insets, 10 mm. Mean ± SEM. p values a
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S3.
3318 Cell Reports 23, 3312–3326, June 12, 20181997). To confirm this effect in vitro, we performed FACS analysis
of KPC cells treated with each inhibitor at 0.1% oxygen (Fig-
ure 4F). Here, we observed a significant arrest of TH-302-treated
cells in G2/M, which we verified by observing HistoneH3(Ser10)
accumulation (Figure 4G). TH-302 induces DNA damage in cells
throughout the entire cell cycle, but our data suggest that in hyp-
oxia TH-302-damaged cells arrest just prior to mitotic entry. This
is likely to greatly enhance the mTORC1/2 inhibition of cells that
escape this arrest (Figure 4H). Indeed,mTORC1 is independently
regulated during mitosis and is required for efficient transit
through the G2/M transition, and cytokinesis (Ramı´rez-Valle
et al., 2010). Furthermore,mTORC2hasbeen shown tobeessen-
tial for S and G2/M cell cycle progression after treatment with a
DNA-damaging agent (Selvarajah et al., 2015). This may partially
explain the additive effect found in the combination therapy (Fig-
ure 4H). These readouts however, do not provide any details with
regard to the treatment-inducedmodulation of PI3K pathway ac-
tivity, within both the hypoxic and normoxic tumor compart-
ments. We therefore chose to track the hypoxic tumor regions,
as an initial step toward mapping drug response.
Mapping of Transient Hypoxic Tumor Regions In Vivo
In order to map tumor hypoxia in more detail, we assessed
the temporal change in the distribution of hypoxia over a 24-hr
period. To track hypoxia, we employed both theGEMand subcu-
taneous KPC PDAC models, treating with the 2-nitroimidazole
hypoxia markers EF5 (Lord et al., 1993) and pimonidazole (Varia
et al., 1998). These markers were either co-injected or adminis-
tered 24 hr apart. As expected, when the probes were co-
injected, there was a strong co-localization of the two markers,
with a large overlap of the immunofluorescence signals (Figure 5).
Notably, when the EF5 and pimonidazole injections were stag-
gered, 24 hr apart, we observed a distinct shift between the
two markers and the overlap of the signals decreased (Figure 5).
This effectwasalsoobserved in theKPflCGEMmodel (FigureS4).
Such a significant decrease in overlap in the staggered condition
reveals that hypoxia moves transiently around the tumor. Many
groups have described the important function of metabolic
reprogramming over oxygen gradients, associated with the aber-
rant vascular networks that give rise to the formation of hypoxia in
many cancers (Rodenhizer et al., 2016; Shukla et al., 2017). In
such a rapid disease model, it then does not seem surprising
that oxygen gradients should move around the tumor. This has
important implications for cancer therapies, as the resistance
that is associated with the hypoxic compartment may also transit
between tumor regions. Fortunately, the use of HAPs, which
become more active in these hypoxic regions, allows treatmentsTH-302 (50 mg/kg) and AZD2014 (2.5 mg/kg)
of tumors over 7 days from vehicle/saline (n = 10), vehicle/TH-302 (n = 9),
essed for the proliferative marker Ki67 (n = 5 tumors/treatment) (C) and DNA
ts, 10 mm. Mean ± SEM.
IHC) (F) tumor fractions from vehicle/saline (n = 10), vehicle/TH-302 (n = 9),
, 1 mm; insets, 100 mm. Mean ± SEM.
nsets, 10 mm. Mean ± SEM.
10), vehicle/TH-302 (n = 9), AZD2014/saline (n = 10), and AZD2014/TH-302
re from a Student two-tailed parametric t test in all panels.
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Figure 4. Characterization of the Cell Cycle Response of KPC Subcutaneous Xenografts Treated with TH-302 (50 mg/kg) and AZD2014
(2.5 mg/kg)
(A) IHC staining of drug response in tumors assessed for the mitosis marker HistoneH3(Ser10) (n = 5 tumors/treatment). Scale bars, 100 mm; insets, 10 mm.
Mean ± SEM. p values are from a Student two-tailed parametric t test.
(B–E) Phenotypic quantification of four distinguishable stages of mitosis, namely late G2 (B), prophase (C), metaphase (D), and anaphase (E), where
HistoneH3(Ser10) presents a unique phenotype. Scale bars, 10 mm. Mean ± SEM. p values are from a Student two-tailed parametric t test.
(F) Propidium iodide staining of cell cycle phase distribution in KPC primary PDAC cells after treatment with AZD2014 (500 nM) and/or TH-302 (1 mM) at 0.1%
oxygen. Mean ± SEM. p values were calculated using a two-way ANOVA with a Tukey correction for multiple comparisons.
(G) HistoneH3(Ser10)/propidium iodide dual-parameter FACS analysis of KPC primary PDAC cells after treatment with AZD2014 (500 nM) and/or TH-302 (1 mM) at
0.1% oxygen. Mean ± SEM. p values are from a Student two-tailed parametric t test.
(H) Schematic representation of the proposed combination effect of AZD2014 on cells prior to mitotic entry by TH-302.
*p < 0.05, **p < 0.01, and ***p < 0.001.to effectively hijack this phenomenon to release cytotoxics by a
local bystander effect and potentially to reduce the hypoxia-
induced resistance we have observed in vivo.
Development of a Dual Imaging Modality for Parallel
Monitoring of PI3K Pathway Activity and Tumor Oxygen
Content in Live Cells
Having established the transient nature of the hypoxic gradients
within the tumor, we then developed a method for live tracking ofboth drug response and oxygen content by real-time IVM. In
contrast to static readouts, IVM provides a dynamic means to
measure single-cell responses within their native microenviron-
ment (Conway et al., 2014, 2017; Ellenbroek and van Rheenen,
2014). Initially, KPC cells were engineered to stably express
the Eevee-Akt-mT2 FRET biosensor, which undergoes a
conformational change in response to phosphorylation by Akt
at a specific consensus sequence and so an increase in the
FRET efficiency, which can be monitored using FLIM-FRETCell Reports 23, 3312–3326, June 12, 2018 3319
AB KPC (xenograft)
Figure 5. Tracking of Tumor Hypoxia with
EF5 and Pimonidazole
(A and B) Immunofluorescence of (A) KPC GEM
tumors and (B) KPC xenograft tumors for EF5 (red)
and pimonidazole (green), chemical indicators
of tumor hypoxia, after either (i) co-injection or
(ii) 24-hr delayed treatments. Scale bars, 100 mm.
(iii) Quantification of overlapping (yellow) regions of
staining between EF5 and pimonidazole in KPC
GEM tumors (n = 3mice/group) and KPC xenograft
tumors (n = 4 mice/group). Mean ± SEM. p values
are from a Student two-tailed parametric t test in all
panels.
See also Figure S4.(Figure S5A) (Komatsu et al., 2011). Expression of this FRET
biosensor caused no detectable change in the response of
KPC cells to hypoxia, which also demonstrated a similar pattern
of resistance for all three PI3K pathway inhibitors (Figures S5B–
S5E). Akt is a key effector of the PI3K pathway and is inactivated
by AZD2014 through mTORC2 inhibition (Figure S5F) (Driscoll
et al., 2016). Since AZD2014 is weakly autofluorescent, we
used an experimentally measured time-varying background
(TVB) to account for background fluorescence from the cells
and the drug (see Supplemental Experimental Procedures for
details and validation) (Conway et al., 2017). Using FLIM-FRET
imaging, we observed that initial activation of Akt by EGF was
reduced by AZD2014, as expected (Figures S5G–S5J). In
contrast, treatment with the mTORC1 inhibitor rapamycin had
no inhibitory effect on Akt. This is in line with previous reports,
where inhibition of mTORC1 alone instead acts to upregulate
Akt activity through IRS1 (O’Reilly et al., 2006). Having estab-
lished the specificity of the Eevee-Akt-mT2 FRET biosensor
and the significant response of the biosensor-expressing cells
to treatment with AZD2014, we next developed amethod for par-
allel monitoring of oxygen content by dual FLIM/PLIM imaging.
The first step toward our dual imaging modality was to assess
the effect of low oxygen levels on the activity of Akt by FLIM-FRET
microscopy, and in linewith thewestern blot assessment (Figures
1D and S5B), we found a significant increase in Akt activity in hyp-
oxia (1% and 0.1% oxygen) compared to normoxia (Figure S6A).
An emerging option for live imaging of tumor oxygen content is
through the use of oxygen-sensitive ruthenium, platinum, or
iridium complexes as nanoparticles (Conway et al., 2017; Kalinina
et al., 2016; Kondrashina et al., 2012; Zheng et al., 2015).3320 Cell Reports 23, 3312–3326, June 12, 2018Recently, imaging of the intrinsic auto-
fluorescence of NAD(P)H/FAD+ was com-
bined with PLIM of an oxygen-sensitive
ruthenium complex (Kalinina et al., 2016).
This approach used on-off modulation of
the pulsed laser source on a microsecond
timescale to allow measurements of
the longer oxygen-sensitive phosphores-
cence decays (Kalinina et al., 2016).
Here, we took a similar approach, using
an electro-optic modulator (EOM) to
switch a multiphoton laser at low fre-
quency (Figure 6A). This allowed us todetect both the short FLIM decays (nanosecond scale) from the
Eevee-Akt-mT2 biosensor, and the much longer phosphores-
cence decays (microsecond scale) of an oxygen-sensitive nano-
particle (Figure 6A).
In order to validate our approach in vitro, we placed glass cov-
erslips over KPC cell monolayers to reduce the oxygen concen-
tration (Figure 6B). First, however, we characterized the applica-
tion of this coverslip hypoxia induction by staining cells for
nuclear HIF1a stabilization and pimonidazole adduct formation,
and observed a significant increase in both after 2 hr, equivalent
to 0.1% or 1% oxygen incubations (Figures 6B and S6B; quan-
tified in Figures S6C and S6D). Furthermore, we assessed the
response of cells under a coverslip by quantitative real-time
PCR (qRT-PCR) for genes characteristically upregulated under
hypoxic conditions and found a significant upregulation of
Slc2a1 (GLUT1), Slc2a3 (GLUT3), Ldha (lactate dehydrogenase
A), P4ha2 V1/V2 (prolyl 4-hydroxylase), Ndrg1, and Adm (adre-
nomedullin) (Figure 6C) (Miller et al., 2015; Shukla et al., 2017).
In this way, we could confirm that a 2-hr incubation with a glass
coverslip was sufficient to decrease oxygen levels and relieve
the oxygen-dependent quenching of MitoImage NanO2, which
led to a significant increase in the PLIM (Figure 6D, top panel;
note shift in PLIM from blue to orange/red upon decrease in
oxygen content). In parallel, we were able to track the activity
of Akt in the same cells by FLIM-FRET microscopy of the
Eevee-Akt-mT2 intramolecular FRET biosensor and observed a
significant increase in the FRET efficiency, consistent with an in-
crease in Akt activity (Figure 6D, bottom panel; note shift in FLIM
from orange to blue). As an additional confirmation, we treated
parental KPC cells with MitoImage MM2, which is composed
Figure 6. Dual FLIM/PLIM Imaging of KPC Cells Stably Expressing the Eevee-Akt-mT2 Intramolecular FRET Biosensor, Treated with
Oxygen-Sensitive Nanoparticles
(A) A schematic illustration of the methodology applied to modify the multiphoton FLIM detection system to detect oxygen-sensitive PLIM through modulation of
the EOM.
(B) A schematic demonstrating the use of a glass coverslip to induce a hypoxic response in vitro.
(C) qRT-PCR analysis of relative mRNA expression of hypoxia response genes upregulated in cells incubated for 2 hr in hypoxia (5%, 1%, and 0.1% oxygen) or
under a coverslip, compared to normoxia, normalized to Rplp0 (n = 5). Mean ± SEM.
(D) Dual FLIM/PLIM imaging of Akt activity in KPC cells treated with MitoImage NanO2 and incubated with a glass coverslip for 1 or 2 hr (n = 4). Scale bars, 50 mm;
insets, 10 mm. Mean ± SEM. p values are from a Student two-tailed parametric t test in all panels.
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figures S5 and S6, and Tables S1 and S2.
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of an oxygen-sensitive phosphorescent (PtTFPP) and oxygen-
insensitive fluorescent (PFO) component that can be read out
ratiometrically, to assess oxygen content (Kondrashina et al.,
2012). By placing a glass coverslip on these cell monolayers,
we observed a significant increase in the ratio of the oxygen-
sensitive PtTFPP to the oxygen-insensitive PFO, consistent
with a decrease in the oxygen content of the cell monolayer
(Figure S6E).
Live Tracking of Tumor Oxygen Content Allows Real-
Time Assessment of Drug Response by IVM
Having established the dual FLIM/PLIM imaging methodology
for in vitro imaging, we next assessed the effect of the combina-
tion therapy on Akt activity in a live setting. Consistent with the
tumor growth experiment (Figure 3), mice were given AZD2014
and TH-302, and once subcutaneous xenografts reached a vol-
ume of >350 mm3, where hypoxia is readily observed, tumors
were surgically exposed and treated with the oxygen-sensitive
nanoparticles (Figure 7A) (Conway et al., 2017; Vennin et al.,
2017). Assessing single cells for their response to each treat-
ment, we found no significant difference in Akt activity between
vehicle and TH-302 treatments, as expected (Figure 7B,
compare black plot to red). Conversely, upon treatment with
AZD2014, a significant decrease in Akt activity was recorded
(Figure 7B, compare black plot to blue). Furthermore, when
AZD2014 was used in combination with TH-302, Akt activity
was significantly reduced to a greater degree than AZD2014
monotherapy (Figure 7B, compare blue plot to green). This effect
was then stratified based on the oxygen content by analyzing the
Akt activity of individual cells (FLIM-FRET) and the oxygen con-
tent by PLIM (Figures 7C–7F, top panel, Akt activity [FLIM-FRET];
bottom panel, oxygen content [PLIM]). In this way, we observed
heterogeneity in Akt activity for vehicle and TH-302 treatments,
as expected (Figures 7C and 7D; plotted in Figures 7G and 7H,
respectively). However, we found that cells treated with
AZD2014 monotherapy had reduced Akt activity predominantly
in the high-oxygen (normoxia) regions and less so in the low-
oxygen (hypoxia) regions (Figure 7E; plotted in Figure 7I). Impor-
tantly, this effect was absent in the combination therapy, where
Akt activity was reduced in both high- and low-oxygen regions
(Figure 7F; plotted in Figure 7J). This confirms and builds upon
our in vitro findings on hypoxia-induced resistance, prompting
further analysis of the in vivo effect of oxygen content on drug
response.
In order to quantify the effect of oxygen content on drug
response, we plotted the fluorescence lifetime from the Eevee-
Akt-mT2 FRET biosensor for Akt activity (FLIM-FRET), against
the phosphorescence lifetime of MitoImage NanO2, as a mea-
sure of oxygen content (PLIM; Figures 7G–7J). Using Deming
regression curves, to account for the error in both parameters
(FLIM-FRET and PLIM), Deming slopes were calculated and
plotted with their 95% confidence bands to highlight the quality
of the fit (Figures 7G–7J). For the vehicle treatment, the Deming
regression slope was not significantly different from zero, which
meant that the error in the slope was sufficiently large and that
the confidence in the slope did not exist (Figure 7G). This was
consistent with the heterogeneous Akt activity in both the vehicle
and TH-302-treated mice (Figure 7K, see black and red bars).3322 Cell Reports 23, 3312–3326, June 12, 2018In the AZD2014 treatment, however, the slope of the regression
was negative and significantly non-zero (Figure 7K, see blue bar).
This identified a significant link between increased Akt activity
and low oxygen content, demonstrating that, in the AZD2014
treatments, there was hypoxia-induced resistance (Figure 7I).
Cumulative assessment of the AZD2014 treatments confirmed
this negative slope was significant, indicating the presence of
hypoxia-induced resistance to AZD2014 monotherapy within
our live tumors (Figure 7K). Furthermore, when AZD2014 treat-
ment was combined with TH-302, this resistance was relieved
(Figure 7K, see green plots), consistent with the improved inhibi-
tion of Akt for the combination treatments (Figure 7B). In this way,
we have identified hypoxia-induced resistance to PI3K pathway
targeting, at the single-cell level, within our live tumors by IVM
and successfully alleviated this in vivo resistance in combination
with the HAP TH-302.
DISCUSSION
Increasingly, our awareness of the context-dependent effects on
treatment efficacy, such as microenvironmental factors and the
influence of tumor-associated immune or stromal components,
is driving the development of more sophisticated IVM ap-
proaches to account for these important contributing factors
(Conway et al., 2017; Ellenbroek and van Rheenen, 2014;
Junankar et al., 2015; Vennin et al., 2017). PDAC has a well-
established hypoxic signature, and this hypoxia was clearly
evident in our GEM and subcutaneous mouse models (Chang
et al., 2011; Miller et al., 2015). Moreover, a hypoxic tumormicro-
environment is strongly associated with treatment-refractory
disease (Sullivan et al., 2008; Wilson and Hay, 2011), and here
we demonstrate hypoxia-induced resistance to three PI3K
pathway inhibitors. This occurs in parallel with an increase in
the activity of Akt, a key effector of the PI3K pathway. In light
of our recent work, demonstrating an equivalent survival benefit
for AZD2014, a dual inhibitor of the PI3K pathway, with standard-
of-care gemcitabine (Driscoll et al., 2016), these data provide
strong support for investigation into the effects of hypoxia on
PI3K pathway targeting.
Given our initial insight into the persistent movement of hypox-
ic regions throughout the tumor, the ability to track and target
this key microenvironmental factor has a clear benefit for pre-
clinical investigations aimed at negating the effects of tumor hyp-
oxia. However, few methods exist for live monitoring of hypoxia
by IVM and they lack the parallel approach that would be
necessary to investigate the effects of hypoxia on therapeutic
response (Conway et al., 2017). For whole-tumor assessment,
many non-invasive positron emission tomography (PET)-based
approaches depend upon the increased glucose uptake of
tumors (Fleming et al., 2015; Rajendran et al., 2004). Of note,
new probes have been developed to provide information on
the hypoxic content of tumors, based on CAIX expression or
2-nitroimidazoles, primarily to guide hypoxia-targeted treatment
strategies (Fleming et al., 2015; Hoeben et al., 2010; Rajendran
et al., 2004). However, for molecular assessment during preclin-
ical drug development, a new approach was necessary to over-
lay tumor oxygen content with therapeutic response by IVM. On
the one hand, genetic markers based on the oxygen degradation
Figure 7. Dual FLIM/PLIM Intravital Imaging of Drug Response and Tumor Oxygen Content
(A) A schematic representation of the intravital imaging setup for the dual FLIM/PLIM imaging. Xenografts of KPC cells stably expressing the Eevee-Akt-mT2
intramolecular FRET biosensor were allowed to reach 350 mm3, before treatment with oxygen-sensitive nanoparticles (NanO2) and dual FLIM/PLIM imaging.
(B) FLIM-FRET analysis of vehicle/saline (n = 5), vehicle/TH-302 (n = 4), AZD2014/saline (n = 7), or AZD2014/TH-302 (n = 4)-treated mice. Mean ± SEM. p values
are from a Student two-tailed parametric t test.
(C–F) Representative FLIM and PLIM maps are provided for cells with a short PLIM value (high oxygen content, normoxic) and a long PLIM value (low oxygen
content, hypoxic) for vehicle/saline (C), vehicle/TH-302 (D), AZD2014/saline (E), and AZD2014/TH-302 (F) treatments. Scale bars, 25 mm.
(G–J) These same cells are then highlighted on their representative Deming regression curves, where blue and red points highlight cells with short or long
PLIM values, respectively. The 95% confidence intervals emphasize whether the slope of the Deming regression is significantly non-zero for vehicle/saline (G),
vehicle/TH-302 (H), AZD2014/saline (I), and AZD2014/TH-302 (J) treatments.
(K) Average Deming slopes of mice from each treatment group, assessed for departure from zero with a one-sample t test. Mean ± SEM.
*p < 0.05, **p < 0.01 and ***p < 0.001.
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domain or hypoxia-response elements of HIF1a are common
(Erapaneedi et al., 2016; Wang et al., 2016), but these may
encounter hurdles for interpretation due to the dysregulation of
the hypoxic response inmany cancers and the necessity tomea-
sure changes in intensity, instead of a switch-like response. On
the other hand, many injectable fluorescent probes exist for
tracking various aspects of tumor hypoxia (O’Connor et al.,
2017; Uddin et al., 2015; Zheng et al., 2015). In this work, appli-
cation of oxygen-sensitive nanoparticles for dual FLIM/PLIM
imaging facilitated live tracking of drug response in the context
of tumor oxygen content. Critically, we identified an oxygen-
dependent resistance effect, at the single-cell level, when treat-
ing tumors with AZD2014monotherapy. This effect was reduced
in vivo, when AZD2014 was combined with the HAP TH-302,
leading to improved inhibition of tumor growth. TH-302 alone,
or in combination with AZD2014, resulted in a decreased hypox-
ic fraction, HIF1a and CAIX expression. This reduction in tumor
hypoxic response was associated with a concomitant reduction
in overall resistance to PI3K pathway targeting and provides a
possible explanation for the improved reduction in Akt activity
in the combination therapies.
Preclinical IVM experiments can provide a robust method to
assess combination therapies aimed at reducing resistant pop-
ulations and improving therapeutic responses. This possibility
has yet to be fully exploited for the known hypoxia-induced
resistance to targeted therapeutics aimed at tyrosine kinase,
HER2, and VEGF pathways (Ahmadi et al., 2014; Bergers and
Hanahan, 2008; Karakashev and Reginato, 2015), as well as
chemotherapies (Shukla et al., 2017; Sullivan et al., 2008),
and highlights the clinical need to track and understand this
hypoxia-induced resistance. Intramolecular FRET biosensors
already exist to read out the activity of many of these pathways,
while the development of simplified backbones for fluorescent
protein reporters or FRET biosensors provides a rapid
approach to develop readouts for therapeutic response within
a live tumor context (Conway et al., 2014, 2017; Komatsu
et al., 2011). As demonstrated here and elsewhere, the addition
of HAPs as a combination therapy provides a suitable
approach to reduce the resistant effects of hypoxia with
reduced additive toxicity (O’Connor et al., 2016; Wilson and
Hay, 2011). By applying IVM using fluorescent protein reporters
or FRET biosensors and parallel imaging of tumor hypoxia, the
benefits observed here for targeting of the PI3K pathway, in
combination with HAPs, can be applied to develop combination
therapies with robust preclinical validation.EXPERIMENTAL PROCEDURES
Animal Experiments
All animal experiments were conducted in compliance with Garvan Ethics
Committee guidelines (13/17 and 16/13 protocols) and in accordance with
the Australian code of practice for the care and use of animals for scientific
purposes, with genotyping performed by Garvan Molecular Genetics (Sydney,
NSW, Australia). Both male and female KPflC and KPC GEM were monitored
for swollen abdomen, cachexia, and reduced mobility until tumor was evident
by palpation, and hypoxia markers were administered (Hingorani et al., 2003,
2005; Morton et al., 2010). For xenografts experiments, 1 3 106 KPC primary
PDAC cells in PBS were subcutaneously injected into the rear flank of 6- to
10-week-old female BALB/c-Fox1nuAusb mice.3324 Cell Reports 23, 3312–3326, June 12, 2018FACS
Cells were fixed in 70% ethanol, prior to staining with propidium iodide
(Sigma-Aldrich; P4170; 1 mg/mL) with RNaseA (Sigma-Aldrich; R6513;
500 mg/mL), and analysis on a FACSCanto II (BD Biosciences). Quantification
was performed in FlowJo (Tree Star), and cell cycle phase was determined in
ModFit (Verity Software House).
Intravital FLIM/PLIM Imaging
Xenografts of KPC cells expressing the Eevee-Akt-mT2 FRET biosensor
were imaged at a final volume of 350 mm3, as per the tumor growth studies.
Mice were anesthetized with xylazine (10 mg/kg) and Zoletil (50 mg/kg) and
kept on a heated stage at 37C. Anesthesia was maintained with isoflurane
(3 L; O2, 1 L; vacuum, 1 L/min). Tumors were surgically exposed, as
described previously (Conway et al., 2017; Vennin et al., 2017), prior to
application of MitoImage NanO2 (10 mg; Ibidi; 74151). After 30 min, dual
FLIM/PLIM imaging was performed on a Leica SP8 microscope with a
0.95 numerical aperture (NA), 253 water objective. Analysis of FLIM and
PLIM decays was performed in FLIMfit (Warren et al., 2013) and is pre-
sented as mean lifetime per cell.
Organotypic Assay
Organotypic matrices were generated as described previously (Conway et al.,
2014; Morton et al., 2010; Vennin et al., 2017). Quantification of the invasive
and proliferative indices was performed on pan-cytokeratin (excludes fibro-
blasts) or Ki67-stained sections, respectively.
IC50 Curves
IC50 curves were performed in a 96-well plate format, with 1,000 cells/well.
Cells were incubated for 24 hr after seeding before addition of inhibitors. Plates
were assessed for relative cell density using the CellTiter 96 AQueous Cell
Proliferation Assay (Promega; G1111) at 72 hr after addition of each inhibitor,
with parallel plates incubated under standard normoxic or hypoxic (0.1%
oxygen) conditions. IC50 curves were then fit in Prism (GraphPad Software),
normalizing to the vehicle (DMSO) control treatments from the respective
normoxic or hypoxic (0.1% oxygen) conditions.
Statistical Analysis
Statistical tests were performed in Prism (GraphPad Software) with statistical
significance given as *p < 0.05, **p < 0.01, and ***p < 0.001 in all cases. A one-
sample t test was performed on normalized data. For IC50 curve comparisons,
an extra sum-of-squares F test was performed between the best-fit parame-
ters of each curve. Deming regression curves for the dual FLIM/PLIM analysis
were plotted with the ‘‘mcr’’ package of R, using the analytical method to
calculate the 95%confidence intervals. To assesswhether the Deming regres-
sion slopes were significantly non-zero, a one-sample t test was performed.
DNA cell cycle analysis was assessed for significance using a two-way
ANOVA test with a Tukey correction for multiple comparisons. In all other
cases, a Student two-tailed parametric t test was performed.
Detailed protocols can be found in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.05.038.
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